Judith Bosschieter

ORCID: 0000-0002-0718-897X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Epigenetics and DNA Methylation
  • Urological Disorders and Treatments
  • Colorectal Cancer Screening and Detection
  • Esophageal Cancer Research and Treatment
  • Urinary Tract Infections Management
  • Urinary Bladder and Prostate Research
  • Renal cell carcinoma treatment
  • Surgical Simulation and Training
  • Hemodynamic Monitoring and Therapy
  • Endometrial and Cervical Cancer Treatments
  • Polyamine Metabolism and Applications
  • Hernia repair and management
  • Cervical Cancer and HPV Research
  • Pelvic floor disorders treatments
  • Abdominal Surgery and Complications
  • Diversity and Career in Medicine
  • Ureteral procedures and complications
  • Multiple and Secondary Primary Cancers
  • Colorectal Cancer Surgical Treatments
  • Prostate Cancer Diagnosis and Treatment
  • Healthcare Policy and Management
  • Cancer Genomics and Diagnostics
  • Anorectal Disease Treatments and Outcomes

Amsterdam University Medical Centers
2019-2025

Vrije Universiteit Amsterdam
2019-2025

University of Amsterdam
2023

The Netherlands Cancer Institute
2014-2020

Amsterdam UMC Location Vrije Universiteit Amsterdam
2017-2020

10.1016/j.euo.2020.12.002 article EN European Urology Oncology 2021-01-12

Abstract Background The development of accurate urinary biomarkers for non-invasive and cost-effective detection primary recurrent bladder tumours is recognized as one the major clinical needs in cancer diagnostics . purposes this study were (1) to validate results a previous technical comparison by determining diagnostic performance nine methylation markers urine pellet compared full void urine, (2) optimal marker panel GHSR/MAL from exploratory preclinical setting. Methods Urine samples...

10.1186/s13148-022-01240-8 article EN cc-by Clinical Epigenetics 2022-02-05

Background Urine poses an attractive non-invasive means for obtaining liquid biopsies oncological diagnostics. Especially molecular analysis on urinary DNA is a rapid growing field. However, optimal and practical storage conditions that result in preservation of DNA, particular hypermethylated (hmDNA), are yet to be determined. Aim To determine the most urine adequate hmDNA analysis. Methods yield use methylation was determined by quantitative specific PCR (qMSP) targeting ACTB RASSF1A genes...

10.1371/journal.pone.0200906 article EN cc-by PLoS ONE 2018-08-24

Ta grade 3 (G3) non–muscle-invasive bladder cancer (NMIBC) is a relatively rare diagnosis with an ambiguous character owing to the presence of aggressive G3 component together lower malignant potential component. The European Association Urology (EAU) NMIBC guidelines recently changed risk stratification for from high intermediate, high, or very risk. However, prognostic studies on carcinomas are limited and inconclusive. To evaluate value categorizing compared G2 T1 carcinomas. Individual...

10.1016/j.euo.2023.01.004 article EN cc-by European Urology Oncology 2023-01-19

DNA methylation analysis of full void urine and pellet seems promising for bladder cancer (BC) detection surveillance. Urinary cell-free from supernatant is now gaining interest other molecular tests in BC. This study aims to evaluate which fraction preferred BC diagnosis using markers: urine, or supernatant. Methylation levels nine markers were determined the three fractions correlated with their respective tumor tissues patients compared controls. For all marker panel GHSR/MAL, diagnostic...

10.3390/cancers12040859 article EN Cancers 2020-04-02

To analyze the potential of 14 cancer-associated genes, including six miRNAs, for bladder cancer (BC) diagnosis in urine.DNA methylation levels genes were analyzed urine 72 BC patients and 75 healthy controls using quantitative methylation-specific PCR. Multivariate logistic regression analysis was used to determine an optimal marker panel.Ten significantly hypermethylated patients. The GHSR/MAL combination showed best diagnostic performance, reaching a sensitivity 92% (95% CI: 86-99)...

10.2217/epi-2018-0094 article EN Epigenomics 2019-02-01

To compare the prognostic value of World Health Organization (WHO) 1973 and 2004 classification systems for grade in T1 bladder cancer (T1-BC), as both are currently recommended international guidelines.Three uro-pathologists re-revised slides 601 primary (first diagnosis) T1-BCs, initially managed conservatively (bacille Calmette-Guérin) four hospitals. Grade was defined according to WHO1973 (Grade 1-3) WHO2004 (low-grade [LG] high-grade [HG]). This resulted a lack 1 tumours, 188 (31%) 2,...

10.1111/bju.14238 article EN BJU International 2018-04-11

Although cystoscopy is a reliable tool for detecting bladder cancer, it poses high burden on patients and entails costs. This highlights the need non-invasive cost-effective alternatives. study aimed to validate previously developed urinary methylation marker panel containing GHSR MAL.

10.1007/s00345-024-05287-5 article EN cc-by World Journal of Urology 2024-10-16

To investigate whether the timing of an immediate instillation mitomycin C (on day transurethral resection bladder tumour [TURBT] or 1 later) has impact on time to recurrence non-muscle-invasive cancer (NMIBC).All patients with NMIBC who were enrolled in a prospective trial between 1998 and 2003, treated early TURBT later), selected. Statistical analysis was performed Kaplan-Meier curves multivariable Cox regression.Administering later did not show statistically significant difference...

10.1111/bju.14124 article EN BJU International 2018-01-10

Ureteroinguinal herniation is a rare event, usually diagnosed during the surgical repair of inguinal hernias. Here, we describe first case kidney blow out due to this condition in male infant.

10.1159/000449015 article EN cc-by-nc-nd Urologia Internationalis 2016-08-26
Coming Soon ...